<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12367">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00492336</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00043807</org_study_id>
    <secondary_id>H-27877</secondary_id>
    <nct_id>NCT00492336</nct_id>
  </id_info>
  <brief_title>Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia</brief_title>
  <official_title>Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanley Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of a new medication for the treatment of cognitive impairments (thinking
      difficulties) and negative symptoms in people with schizophrenia. The new medication is
      rasagiline. Rasagiline is a drug which has been approved by the Food and Drug Administration
      for the treatment of Parkinson's disease. It is used to treat cognitive problems.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will consist of two phases: a 4-week continued stability phase (lead-in phase) and
      a 12-week double-blind treatment phase. In the lead-in phase, subjects receiving
      antipsychotic medication, who manifest moderate to severe and persistent negative symptoms,
      will remain on their maintenance regimen for at least four weeks. The treatment phase will
      be a 12-week, parallel groups, double-blind, placebo-controlled trial of adjunctive
      rasagiline (1 mg/day), a selective MAO-B oxidase inhibitor.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Scale for the Assessment of Negative Symptoms (SANS)</measure>
    <time_frame>Every 4 weeks over a 12 week period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Scores on the subscales are combined (summed) to compute a total score. There are a total of 17 subscales. Each subscale ranges from 0=&quot;Not at all&quot; to 5=&quot;Severe&quot;. Every 4 weeks the summed subscale scores provide a total score for that week (0-85). These total scores from each week are then combined (summed) for an overall score and then averaged for the two groups after the 12 week period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological Tests, Including RBANS, Probabilistic Learning Task, and N-Back Task</measure>
    <time_frame>Beginning of treatment phase (week 0) and end of treatment phase (week 12)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Simpson Angus Scale</measure>
    <time_frame>Every 4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effect Checklist and Vital Signs</measure>
    <time_frame>Weekly</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Rasagiline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with Rasagiline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inactive pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment with Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rasagiline (Pharmacodynamics)</intervention_name>
    <description>Rasagiline 1 mg/day for 12 weeks</description>
    <arm_group_label>Rasagiline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 1 tablet each day</description>
    <arm_group_label>Inactive pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects will meet DSM-IV criteria for schizophrenia or schizoaffective disorder.

          -  Current treatment with one or more second generation antipsychotics, except
             ziprasidone

          -  On same second generation antipsychotic(s)for at least 56 days

          -  On same dose of second generation antipsychotic(s)for at least 30 days

          -  22-item SANS: Total score (i.e.all items minus global items and poverty of content of
             speech)greater than 20 or global Rating of Affective Flattening greater than or equal
             to 3 or global Rating of alogia greater than or equal to 3

          -  BPRS: Sum of the four positive symptom items less than or equal to 16 (items
             4,11,12,15)

          -  BPRS: Sum of the four Anxiety/Depression Factor items less than or equal to 14 (items
             1,2,5,9)

          -  Simpson-Angus Scale: Total score less than or equal to 8

        Exclusion Criteria:

          -  DSM-IV Major Depressive Disorder within last 6 months

          -  Current treatment with ziprasidone

          -  DSM-IV diagnosis of alcohol or substance dependence within the last 6 months

          -  DSM-IV criteria for alcohol or substance abuse within the last month

          -  evidence of illicit substance use, as identified with urine toxicology screen

          -  History of an organic brain disorder, mental retardation,epilepsy, or a medical
             condition, whose pathology or treatment could alter the presentation or treatment of
             schizophrenia or significantly increase the risk associated with the proposed
             treatment protocol. See those listed below

          -  Uncontrolled hypertension defined as BP exceeding 145/90 on 3 consecutive readings
             despite adequate treatment, pheochromocytoma, melanoma, hepatic insufficiency

          -  Pregnancy or lactation in females

          -  Pheochromocytoma

          -  Melanoma

          -  Hepatic insufficiency
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert W Buchanan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baltimore VA Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keypoint Mental health Center</name>
      <address>
        <city>Catonsville</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland Psychiatric REsearch Center</name>
      <address>
        <city>Catonsville</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mosaic Community Mental health Center</name>
      <address>
        <city>Catonsville</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keypoint Mental health Center</name>
      <address>
        <city>Dundalk</city>
        <state>Maryland</state>
        <zip>21222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 17, 2013</lastchanged_date>
  <firstreceived_date>June 26, 2007</firstreceived_date>
  <firstreceived_results_date>February 1, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland</investigator_affiliation>
    <investigator_full_name>Robert W. Buchanan, M.D.</investigator_full_name>
    <investigator_title>Chief, Maryland Psychiatric Research Center, Outpatient Research Program</investigator_title>
  </responsible_party>
  <keyword>Cognitive impairments</keyword>
  <keyword>Negative symptoms</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rasagiline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited between May 2007-October 2011 from mental health clinics throughout the community.</recruitment_details>
      <pre_assignment_details>Participants were excluded before assignment to treatment groups if they met any of the exclusion criteria, if they became clinically unstable, or they decided that the demands of the study were too great. 84 participants were enrolled into active participation; 57 started study treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Rasagiline</title>
          <description>Treatment with Rasagiline</description>
        </group>
        <group group_id="P2">
          <title>Inactive Pill</title>
          <description>Treatment with Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rasagiline</title>
          <description>Treatment with Rasagiline</description>
        </group>
        <group group_id="B2">
          <title>Inactive Pill</title>
          <description>Treatment with Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="28"/>
                <measurement group_id="B2" value="29"/>
                <measurement group_id="B3" value="57"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="28"/>
                <measurement group_id="B2" value="29"/>
                <measurement group_id="B3" value="57"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="46.3" spread="12.2"/>
                <measurement group_id="B2" value="45.9" spread="11.1"/>
                <measurement group_id="B3" value="46.09" spread="11.59"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="11"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="24"/>
                <measurement group_id="B2" value="22"/>
                <measurement group_id="B3" value="46"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="28"/>
                <measurement group_id="B2" value="29"/>
                <measurement group_id="B3" value="57"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Scale for the Assessment of Negative Symptoms (SANS)</title>
        <description>Scores on the subscales are combined (summed) to compute a total score. There are a total of 17 subscales. Each subscale ranges from 0=&quot;Not at all&quot; to 5=&quot;Severe&quot;. Every 4 weeks the summed subscale scores provide a total score for that week (0-85). These total scores from each week are then combined (summed) for an overall score and then averaged for the two groups after the 12 week period.</description>
        <time_frame>Every 4 weeks over a 12 week period</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Rasagiline</title>
            <description>Treatment with Rasagiline</description>
          </group>
          <group group_id="O2">
            <title>Inactive Pill</title>
            <description>Treatment with Placebo</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Scale for the Assessment of Negative Symptoms (SANS)</title>
            <description>Scores on the subscales are combined (summed) to compute a total score. There are a total of 17 subscales. Each subscale ranges from 0=&quot;Not at all&quot; to 5=&quot;Severe&quot;. Every 4 weeks the summed subscale scores provide a total score for that week (0-85). These total scores from each week are then combined (summed) for an overall score and then averaged for the two groups after the 12 week period.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="32.5" spread="8.5"/>
                  <measurement group_id="O2" value="33.5" spread="7.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neuropsychological Tests, Including RBANS, Probabilistic Learning Task, and N-Back Task</title>
        <time_frame>Beginning of treatment phase (week 0) and end of treatment phase (week 12)</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Simpson Angus Scale</title>
        <time_frame>Every 4 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effect Checklist and Vital Signs</title>
        <time_frame>Weekly</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Rasagiline</title>
          <description>Treatment with Rasagiline</description>
        </group>
        <group group_id="E2">
          <title>Inactive Pill</title>
          <description>Treatment with Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>tooth problems</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>conceptual disorganization</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>increased urinary frequency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Robert Buchanan, M.D.</name_or_title>
      <organization>Maryland Psychiatric Research Center</organization>
      <phone>410-402-7876</phone>
      <email>rwbuchanan@mprc.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
